Joost S.P. Vermaat

3.2k citations

74 papers · 1.6k indexed · h-index 17

Cancer Research top 5%
Oncology top 5%
- CAR-T cell therapy research 18
- Viral-associated cancers and disorders 11
Pathology and Forensic Medicine top 5%
- Lymphoma Diagnosis and Treatment 46
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 18
Dermatology top 5%
- Cutaneous lymphoproliferative disorders research 10
Neurology
- CNS Lymphoma Diagnosis and Treatment 9
Pulmonary and Respiratory Medicine
- Renal cell carcinoma treatment 6
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 6

Co-authors: Emile E. Voest Niven Mehra Laurens V. Beerepoot Bernard A. Zonnenberg Jeanine M.L. Roodhart P. J. van Diest Rachel H. Giles Patrick W.B. Derksen
Cited by: Cancer Research Oncology Pathology and Forensic Medicine
Journals: Journal of Clinical Investigation (1 paper)The Journal of Experimental Medicine (1 paper)Journal of Clinical Oncology (3 papers)
Partner nations: Netherlands United States Belgium

In The Last Decade

Joost S.P. Vermaat

64 papers receiving 1.6k citations

Peers

Countries citing papers authored by Joost S.P. Vermaat

Since Specialization

Citations

This map shows the geographic impact of Joost S.P. Vermaat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joost S.P. Vermaat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joost S.P. Vermaat more than expected).

Fields of papers citing papers by Joost S.P. Vermaat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joost S.P. Vermaat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joost S.P. Vermaat. The network helps show where Joost S.P. Vermaat may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Joost S.P. Vermaat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joost S.P. Vermaat Line = papers co-authored together Joost S.P. Vermaat links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma Blood ·Marie José Kersten,Kirsten Saevels,Évelyne Willems,Marte C. Liefaard,Stavros Milatos,Margot J. Pont,Claire Vennin,Eva Santermans,Anna D.D. van Muyden,Jeevan K. Shetty,Esmée P. Hoefsmit,Omotayo Fasan,Maria T. Kuipers,Sébastien Anguille,Joost S.P. Vermaat	2024	1
2	IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7 Clinical Lymphoma Myeloma & Leukemia ·Lorenzo Falchi,Joost S.P. Vermaat,Gerardo Musuraca,Marcel Nijland,Jacob Haaber Christensen,Fritz Offner,Lori A. Leslie,Joshua Brody,Daniela Hoehn,Jennifer Marek,Liwei Wang,Jian Mei,David Belada,Pau Abrisqueta	2024	1
3	Detection of Circulating Tumor DNA for Disease Monitoring in Patients with Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type Journal of Investigative Dermatology ·Anne M.R. Schrader,Julia van Engeland,Rein Willemze,Joost S.P. Vermaat,Rosanne Ottevanger,Juliette M. Kersten,Willem H. Zoutman,Patty M. Jansen,Ronald van Eijk,Demi van Egmond,Mieke Versluis,Koen D. Quint,Maarten H. Vermeer	2024	2
4	Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL The Journal of Experimental Medicine ·Janneke A. Eken,Marvyn T. Koning,Kristýna Kupcová,Julieta Sepúlveda-Yáñez,Ruben A. L. de Groen,Edwin Quinten,Jurriaan Janssen,Cornelis A.M. van Bergen,Joost S.P. Vermaat,Arjen H.G. Cleven,Marcelo A. Navarrete,Bauke Ylstra,Daphne de Jong,Ondřej Havránek,Hassan Jumaa,Hendrik Veelken	2024	5
5	Population Pharmacokinetic and Toxicity Analysis of High-Dose Methotrexate in Patients with Central Nervous System Lymphoma Clinical Pharmacokinetics ·Anyue Yin,Fleur A. de Groot,Henk‐Jan Guchelaar,Marcel Nijland,Jeanette K. Doorduijn,Daan J. Touw,Thijs H. Oude Munnink,Brenda C. M. de Winter,Lena E. Friberg,Joost S.P. Vermaat,Dirk Jan A. R. Moes	2024	3
6	Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry Blood Advances ·Mirian Brink,Francien Huisman,Frederik O. Meeuwes,Marjolein van der Poel,Marie José Kersten,Mariëlle J. Wondergem,Lara H. Böhmer,Feng Jung Sherida H. Woei-A-Jin,Otto Visser,Rimke Oostvogels,Patty M. Jansen,Arjan Diepstra,Tjeerd J.F. Snijders,Gerwin Huls,Joost S.P. Vermaat,Wouter J. Plattel,Marcel Nijland	2024	7
7	Enteropathy‐associated T‐cell lymphoma: A population‐based cohort study on incidence, treatment, and outcome in the Netherlands SHILAP Revista de lepidopterología ·Frederik O. Meeuwes,Mirian Brink,Wouter J. Plattel,Joost S.P. Vermaat,Marie José Kersten,Mariëlle J. Wondergem,Otto Visser,Marjolein van der Poel,Rimke Oostvogels,Feng Jung Sherida H. Woei-A-Jin,Lara H. Böhmer,Tjeerd J.F. Snijders,Gerwin Huls,Marcel Nijland	2024	0
8	Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial Blood ·Lori A. Leslie,Chan Y. Cheah,Franck Morschhauser,Justin Darrah,Joshua Brody,David Belada,Juraj Ďuraš,Joost S.P. Vermaat,Gerardo Musuraca,Kojo Osei-Bonsu,Yi Hao,Kimberly G. Archer,Monica Wielgos-Bonvallet,Ali Rana,Yasmin Karimi	2024	5
9	Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial Blood ·Lorenzo Falchi,Anna Sureda,Sirpa Leppä,Joost S.P. Vermaat,Marcel Nijland,Jacob Haaber Christensen,Sven de Vos,Harald Holte,Reid W. Merryman,Pieternella J. Lugtenburg,Pau Abrisqueta Costa,Kim Linton,Gauri Sunkersett,Christopher Morehouse,Andrew J. Steele,Jennifer Marek,Liwei Wang,Daniela Hoehn,Martin Hutchings,David Belada	2024	5
10	The Genetic Profile of Large B-Cell Lymphomas Presenting in the Ocular Adnexa International Journal of Molecular Sciences ·Stine Dahl Vest,Patrick René Gerhard Eriksen,Fleur A. de Groot,Ruben A. L. de Groen,Anne H. R. Kleij,Marina Knudsen Kirkegaard,Peter Kamper,P Rasmussen,Christian von Buchwald,Peter de Nully Brown,Jens Folke Kiilgaard,Joost S.P. Vermaat,Steffen Heegaard	2024	0
11	Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands Haematologica ·Frederik O. Meeuwes,Mirian Brink,Wouter J. Plattel,Marjolein van der Poel,Marie José Kersten,Mariëlle J. Wondergem,Lara H. Böhmer,Feng Jung Sherida H. Woei-A-Jin,Otto Visser,Rimke Oostvogels,Patty M. Jansen,Karen J. Neelis,Anne P.G. Crijns,Laurien Daniëls,Tjeerd J.F. Snijders,Joost S.P. Vermaat,Gerwin Huls,Marcel Nijland	2023	5
12	Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities JCO Oncology Practice ·Anne M. Spanjaart,Elise R. A. Pennings,Milan Kos,Pim Mutsaers,Pieternella J. Lugtenburg,Tom van Meerten,Jaap A. van Doesum,Monique C. Minnema,Margot Jak,Suzanne van Dorp,Joost S.P. Vermaat,Marjolein van der Poel,Martijn G.H. van Oijen,Maria T. Kuipers,Inger S. Nijhof,Marie José Kersten	2022	7
13	Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome Cancers ·Johanna Bult,Jéssica Rodrigues Plaça,Erlin A. Haacke,Martijn Terpstra,Gwenny M. Verstappen,Fred K. L. Spijkervet,Frans G. M. Kroese,Wouter J. Plattel,Joost S.P. Vermaat,Hendrika Bootsma,Bert van der Vegt,Arjan Diepstra,Anke van den Berg,Klaas Kok,Marcel Nijland	2022	9
14	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·Anne M.R. Schrader,Ruben A. L. de Groen,Rein Willemze,Patty M. Jansen,Koen D. Quint,Tom van Wezel,Ronald van Eijk,Dina Ruano,Cornelis P. Tensen,Esther Hauben,Feng Jung Sherida H. Woei-A-Jin,Anne Marie Busschots,Anke van den Berg,Arjan Diepstra,Maarten H. Vermeer,Joost S.P. Vermaat	2022	14
15	Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study Blood Advances ·Mirian Brink,Xaver U. Kahle,Joost S.P. Vermaat,Josée M. Zijlstra,Martine E.D. Chamuleau,Marie José Kersten,Müjde Durmaz,Wouter J. Plattel,Pieternella J. Lugtenburg,Wendy B.C. Stevens,Rogier Mous,Elisabeth G.E. de Vries,Marjolein van der Poel,Prashant V. Nannan Panday,Gerwin Huls,Tom van Meerten,Marcel Nijland	2021	16
16	MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis Haematologica ·Joost S.P. Vermaat,Sebastiaan Somers,Liesbeth C. de Wreede,Willem Kraan,Ruben A. L. de Groen,Anne M.R. Schrader,Emile D. Kerver,Cornelis G. Scheepstra,Henriette W Berenschot,Wendy Deenik,Jurgen Wegman,Rianne Broers,Jan-Paul de Boer,Marcel Nijland,Tom van Wezel,Hendrik Veelken,Marcel Spaargaren,Arjen H.G. Cleven,Marie José Kersten,Steven T. Pals	2019	57
17	High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type The American Journal of Surgical Pathology ·Anne M.R. Schrader,Patty M. Jansen,Maarten H. Vermeer,Johanna K. Kleiverda,Joost S.P. Vermaat,Rein Willemze	2018	37
18	High Prevalence of Oncogenic MYD88 and CD79B Mutations in Intravascular Large B-Cell Lymphoma: Implication for Therapy with Bruton's Kinase Inhibitors? Blood ·Sebastiaan Somers,Patty M. Jansen,Hendrik Veelken,Maarten H. Vermeer,Willem Kraan,Anne-Roos Schrader,Ward Posthuma,Marcel Nijland,Arjan Diepstra,Marie José Kersten,Steven T. Pals,Arjen H.G. Cleven,Joost S.P. Vermaat	2017	1
19	Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment Clinical Cancer Research ·Joost S.P. Vermaat,Isaäc J. Nijman,Marco J. Koudijs,Frank L. Gerritse,Stefan Scherer,Michal Mokrý,Wijnand Roessingh,Nico Lansu,Ewart de Bruijn,Richard van Hillegersberg,P. J. van Diest,Edwin Cuppen,Emile E. Voest	2011	119
20	Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance Journal of Clinical Investigation ·Ron C.J. Schackmann,Miranda van Amersfoort,Judith H.I. Haarhuis,Eva J. Vlug,Vincentius A. Halim,Jeanine M.L. Roodhart,Joost S.P. Vermaat,Emile E. Voest,Petra van der Groep,P. J. van Diest,Jos Jonkers,Patrick W.B. Derksen	2011	107

About Joost S.P. Vermaat

Joost S.P. Vermaat is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology, having authored 74 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (46 papers), Chronic Lymphocytic Leukemia Research (18 papers), CAR-T cell therapy research (18 papers), Viral-associated cancers and disorders (11 papers), Cutaneous lymphoproliferative disorders research (10 papers), CNS Lymphoma Diagnosis and Treatment (9 papers), Renal cell carcinoma treatment (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). The work is most often cited by research in Cancer Research (500 citations), Oncology (727 citations) and Pathology and Forensic Medicine (412 citations). Joost S.P. Vermaat has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Emile E. Voest, Niven Mehra, Laurens V. Beerepoot, Bernard A. Zonnenberg, Jeanine M.L. Roodhart, P. J. van Diest, Rachel H. Giles, Patrick W.B. Derksen, Miranda van Amersfoort and Anne M.R. Schrader. Their work appears in journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact